Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02861131 · ClinicalTrials.gov registry record · Phase 4

The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

A Phase 4 study of Postoperative Complications and Neuromuscular Blockade, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 4
Development phase
200
Enrollment target
1
Study location

NCT02861131: Completed Phase 4 study of Postoperative Complications and Neuromuscular Blockade, sponsored by Oregon Health and Science University.

NCT02861131 is a Phase 4 study of Postoperative Complications and Neuromuscular Blockade that has completed, run by Oregon Health and Science University. The registered enrollment target is 200 participants, below the 552-participant average among 20 other Postoperative Complications trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02861131, a Phase 4 study of Postoperative Complications and Neuromuscular Blockade, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 4
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

Substantial respiratory morbidity has been associated with postoperative residual paralysis, which is fairly common after general anesthesia involving a neuromuscular blocking agent. Common practice in United States is to reverse neuromuscular blockade with neostigmine at the end of surgery. A new drug with evidence of more complete neuromuscular reversal has been developed, sugammadex. The objective of this study is to determine if a strategy of rocuronium neuromuscular reversal with sugammadex will reduce the proportion of subjects with any postoperative pulmonary complication, compared to neostigmine.

Primary Outcome

A composite outcome which includes any of the following: postoperative pneumonia, aspiration pneumonitis, atelectasis, pneumothorax, desaturation/hypoxemia, upper airway obstruction, or acute respiratory insufficiency

Interventions

  • DRUG Sugammadex
  • DRUG Neostigmine

Study Locations (1)

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2017-01-24
Est. Completion 2018-04-30
Phase Phase 4

What the finished NCT02861131 record still lists

NCT02861131 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 552-participant average among 20 other Postoperative Complications trials with a reported enrollment target (64% lower).

The record links to 2 conditions, with Postoperative Complications appearing as the primary indexed condition, and to 2 interventions - of which Sugammadex is the first listed.

NCT02861131 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT02861131 about?

NCT02861131 is a clinical study titled "The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications". Substantial respiratory morbidity has been associated with postoperative residual paralysis, which is fairly common after general anesthesia involving a neuromuscular blocking agent. Common practice in United States is to reverse neuromuscular blockade with neostigmine at the end of surgery. A new d...

What is the current status of trial NCT02861131?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2017-01-24. Estimated completion is 2018-04-30.

What conditions does trial NCT02861131 study?

This clinical trial studies the following conditions: Postoperative Complications, Neuromuscular Blockade.

What interventions are being tested in trial NCT02861131?

The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG).

Who is sponsoring clinical trial NCT02861131?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02861131 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Complications

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02861131's enrollment target sits among peer trials

200 7th of 20 higher than 13 of 20 other Postoperative Complications trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Postoperative Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02861131, the US trial registry maintained by the National Library of Medicine. NCT02861131 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.